ASND
Ascendis Pharma AS
227.90$
+0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 15.4% | 14.1% | 7.9% | 31.8% | 19.4% | 8.1% | 17.4% | 19.9% | 10.5% | 11.1% | 8.6% | 9.4% | 9.8% | |
| 84.6% | 85.9% | 92.1% | 68.2% | 80.6% | 91.9% | 82.6% | 80.1% | 89.5% | 88.9% | 91.4% | 90.6% | 90.2% | |
| 232.0% | 66.0% | 73.7% | 231.9% | 127.2% | 45.6% | 85.8% | 45.5% | 31.3% | 30.6% | 23.0% | 21.6% | 26.0% | |
| 130.1% | 46.5% | 75.4% | 200.8% | 117.8% | 45.3% | 94.7% | 66.9% | 52.3% | 55.1% | 57.9% | 49.8% | 53.5% | |
| 364.4% | 112.5% | 143.4% | 438.3% | 247.9% | 91.7% | 185.9% | 113.6% | 84.4% | 84.9% | 81.3% | 72.2% | 79.8% | |
| -279.8% | -26.6% | -51.2% | -370.2% | -167.3% | 0.2% | -103.2% | -33.5% | 5.1% | 4.0% | 10.1% | 18.4% | 10.4% | |
| 51.0% | 49.8% | 80.5% | 54.5% | 43.8% | 32.6% | 44.4% | 20.9% | 9.2% | 25.0% | 27.3% | 4.2% | 15.5% | |
| -336.4% | -58.9% | -134.0% | -303.2% | -169.8% | -21.5% | -92.7% | -22.2% | -26.9% | -10.8% | -19.5% | 67.8% | 9.6% | |
| 1.3% | 4.2% | 2.6% | 0.6% | 1.8% | 0.6% | 1.1% | 2.4% | 1.7% | 2.8% | -274.7% | 6.8% | -62.1% | |
| -337.7% | -63.1% | -136.6% | -303.9% | -171.5% | -22.1% | -93.7% | -24.6% | -28.5% | -13.6% | 255.2% | 61.0% | 71.7% | |
| -275.5% | -49.2% | -48.9% | -243.1% | -123.0% | -21.8% | -43.8% | 1.5% | -25.0% | 16.2% | 9.4% | 19.7% | 7.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.